Cleveland Clinic Heart Failure Summit 2026 (Videos)

Advanced Heart Failure, Cardiomyopathy, Cardiac Amyloidosis, Cardiogenic Shock, LVAD, ECMO, AI & Precision Cardiovascular Medicine

Stay at the forefront of modern cardiovascular care with the Cleveland Clinic Heart Failure Summit 2026, a comprehensive educational program focused on the latest advances in heart failure, cardiomyopathy, cardiac amyloidosis, cardiogenic shock, mechanical circulatory support, precision medicine, and artificial intelligence.

Presented by internationally recognized faculty from the Cleveland Clinic Heart, Vascular & Thoracic Institute, this extensive program features 41 expert-led video sessions covering the complete spectrum of contemporary heart failure management—from guideline-directed medical therapy (GDMT) and cardio-kidney-metabolic (CKM) syndrome to ECMO, LVAD therapy, heart transplantation, gene therapy, structural heart disease, and emerging digital health technologies.

Designed to bridge cutting-edge research with everyday clinical practice, this course equips clinicians with evidence-based strategies to improve outcomes in patients with acute, chronic, and advanced heart failure.

Product Details

• Course: Cleveland Clinic Heart Failure Summit 2026
• Provider: Cleveland Clinic
• Format: Videos
• Total Sessions: 41 Expert-Led Videos
• Language: English
• Educational Level: Advanced
• Learning Format: Expert Lectures, Clinical Updates, Case-Based Discussions, Evidence-Based Reviews

Course Overview

Heart failure treatment has undergone remarkable transformation with the emergence of novel pharmacologic agents, advanced imaging, precision medicine, metabolic therapies, artificial intelligence, mechanical circulatory support devices, and heart transplantation strategies.

The Cleveland Heart Failure Summit 2026 provides an in-depth review of these advances while helping clinicians integrate the latest clinical trials, guideline recommendations, and technological innovations into daily cardiovascular practice.

Participants will explore practical approaches for managing patients with HFrEF, HFpEF, cardiogenic shock, cardiac amyloidosis, inflammatory and inherited cardiomyopathies, cardio-oncology, structural heart disease, arrhythmias, and cardio-kidney-metabolic disease through expert-led presentations from internationally recognized heart failure specialists.

What You’ll Learn

After completing this course, participants will be able to:

• Optimize evidence-based treatment for patients with HFrEF and HFpEF.
• Apply precision medicine to heart failure management using genetics, imaging, and phenotypic assessment.
• Diagnose and treat cardiac amyloidosis using modern imaging and targeted therapies.
• Recognize advanced heart failure and appropriately refer patients for LVAD or heart transplantation.
• Select temporary and durable mechanical circulatory support strategies.
• Implement AI-driven technologies and remote monitoring into cardiovascular practice.
• Integrate cardio-kidney-metabolic management to improve long-term outcomes.

Comprehensive Topics Covered

Heart Failure Management

Master modern heart failure care.

Topics include:

• Heart Failure
• HFrEF
• HFpEF
• Guideline-Directed Medical Therapy (GDMT)
• Vericiguat
• Digitalis
• Heart Failure Phenotypes
• Contemporary Clinical Trials

Cardiac Amyloidosis

Strengthen diagnosis and treatment.

Topics include:

• Transthyretin (ATTR) Amyloidosis
• AL Amyloidosis
• Nuclear Cardiac Imaging
• Gene Editing
• Disease-Modifying Therapies
• Musculoskeletal Manifestations
• Patient Management

Cardiogenic Shock

Develop advanced critical care strategies.

Topics include:

• Cardiogenic Shock
• Hemodynamic Assessment
• Critical Care
• Vasopressors
• Shock Management
• Temporary Support
• Clinical Decision-Making

Mechanical Circulatory Support

Optimize advanced heart failure interventions.

Topics include:

• ECMO
• VA ECMO
• VAV ECMO
• LAVA ECMO
• Temporary Mechanical Circulatory Support (MCS)
• LVAD Therapy
• Advanced Heart Failure Referral

Heart Transplantation

Improve transplant evaluation and care.

Topics include:

• Heart Transplantation
• Candidate Evaluation
• Organ Allocation
• Continuous Distribution
• End-Stage Heart Failure
• Advanced Therapies
• Long-Term Outcomes

Cardiomyopathy & Precision Medicine

Explore personalized cardiovascular care.

Topics include:

• Genetic Cardiomyopathies
• Cardiac Sarcoidosis
• Inflammatory Cardiomyopathy
• CD36 Variants
• Precision Medicine
• Gene Therapy
• Regenerative Medicine

Artificial Intelligence & Digital Health

Learn next-generation cardiovascular technologies.

Topics include:

• Artificial Intelligence (AI)
• Machine Learning
• Risk Prediction
• Clinical Workflow Integration
• Remote Pulmonary Artery Monitoring
• Digital Health
• Personalized Medicine

Cardio-Kidney-Metabolic (CKM) Care

Integrate multidisciplinary cardiovascular management.

Topics include:

• CKM Syndrome
• Obesity
• Metabolic Disease
• Nutrition
• Exercise
• Population Health
• Equitable Access to Care

Structural Heart Disease & Arrhythmias

Enhance comprehensive cardiovascular care.

Topics include:

• Structural Heart Disease
• TAVR
• Aortic Stenosis
• Atrial Fibrillation
• Catheter Ablation
• Electrophysiology
• Surgical Decision-Making

Selected Featured Sessions

• Cardiac Amyloidosis: Expert Q&A on Diagnosis and Management
• ECMO Cannulation Strategy: Choosing VA, VAV, LAVA and Other Configurations
• Cardiogenic Shock: From Guidelines to Bedside
• Temporary Mechanical Circulatory Support: Right Device, Right Patient, Right Time
• Personalizing Care for LVAD Recipients
• Heart Allocation by Continuous Distribution
• HFpEF and Obesity: SUMMIT Trial
• HFpEF: FINEARTS-HF & RE-DEFINE-HF
• Vericiguat for HFrEF: VICTOR Trial
• The Role of Digitalis in HFrEF
• AI in Heart Failure
• Gene Therapy for Cardiomyopathies
• CKM Care Models
• Cardiac Sarcoidosis Across the EF Spectrum
• Cardio-Oncology in Advanced Heart Failure
• Atrial Fibrillation in Heart Failure
• TAVR in Patients with HFrEF

Learning Objectives

Upon completion of this educational activity, participants will be able to:

• Apply precision medicine principles using genetic, metabolic, imaging, and phenotypic information for patients across the heart failure spectrum.
• Integrate current evidence into guideline-directed medical therapy for HFrEF and HFpEF.
• Interpret major clinical trials and apply findings to individualized patient management.
• Recognize advanced heart failure and appropriately evaluate patients for LVAD therapy, mechanical circulatory support, or heart transplantation.
• Select appropriate ECMO configurations and temporary mechanical circulatory support devices for critically ill patients.
• Improve diagnosis and treatment of transthyretin (ATTR) and AL cardiac amyloidosis.
• Implement cardio-kidney-metabolic care models that improve coordination and equity in heart failure management.
• Utilize artificial intelligence, remote monitoring, advanced imaging, gene therapy, and regenerative medicine to improve cardiovascular outcomes.
• Manage complex cardiovascular patients with structural heart disease, arrhythmias, metabolic disease, inflammatory cardiomyopathies, and cardio-oncology conditions.

Educational Highlights

• Heart Failure
• HFrEF
• HFpEF
• Guideline-Directed Medical Therapy (GDMT)
• Cardiac Amyloidosis
• ATTR Amyloidosis
• AL Amyloidosis
• Cardiogenic Shock
• ECMO
• Mechanical Circulatory Support
• LVAD
• Heart Transplantation
• Cardiomyopathy
• Cardio-Oncology
• Cardiac Sarcoidosis
• Artificial Intelligence (AI)
• Precision Medicine
• Gene Therapy
• Structural Heart Disease
• TAVR
• Cardio-Kidney-Metabolic Syndrome (CKM)
• Atrial Fibrillation
• Continuing Medical Education (CME)

Why This Course Stands Out

The Cleveland Clinic Heart Failure Summit 2026 delivers one of the most comprehensive educational updates available in contemporary heart failure and advanced cardiovascular medicine. Combining 41 expert-led sessions with evidence from landmark clinical trials, guideline updates, precision medicine, AI applications, mechanical circulatory support, cardiac transplantation, and multidisciplinary care models, this program provides clinicians with practical knowledge that directly enhances the diagnosis and management of complex cardiovascular disease.

Target Audience

This educational activity is ideal for:

• Cardiologists
• Heart Failure Specialists
• Internal Medicine Physicians
• Critical Care Physicians
• Cardiac Surgeons
• Electrophysiologists
• Advanced Heart Failure Specialists
• Transplant Cardiologists
• Cardiology Fellows
• Physician Assistants
• Nurse Practitioners
• Critical Care Nurses
• Clinical Pharmacists
• Healthcare Professionals involved in cardiovascular medicine

Why Choose This Course?

Whether you manage chronic heart failure, advanced cardiomyopathy, cardiogenic shock, or transplant candidates, the Cleveland Clinic Heart Failure Summit 2026 provides a world-class update on modern cardiovascular medicine. Through expert-led lectures, case-based discussions, and practical implementation of the latest evidence, participants gain advanced clinical knowledge that improves diagnostic accuracy, optimizes therapeutic decisions, and enhances outcomes for patients across the full spectrum of heart failure.

---

Original Event Information

Cleveland Heart Failure Summit
Dates: June 12–13, 2026
Location: InterContinental Hotel & Conference Center, Cleveland, Ohio

 

#	Topic	Duration
1	Cardiac Amyloidosis: Expert Q&A on Diagnosis and Management	10:41
2	ECMO Cannulation Strategy: Choosing VA, VAV, LAVA, and Other Configurations	18:53
3	Heart Failure: Navigating Complex Clinical Intersections – Panel Discussion	09:36
4	Cardiac Amyloidosis: Best Practices in Nuclear Imaging and Future Directions	15:02
5	Evolutions in TTR Therapies: Matching Therapy to Phenotype	18:37
6	Transthyretin Amyloidosis: Gene Editing Approaches	12:29
7	AL Amyloidosis: Navigating Complex Diagnostic and Treatment Decisions (Case Based)	16:18
8	Cardiac Amyloidosis: Educating Patients After a New Diagnosis	18:23
9	Amyloidosis and the Musculoskeletal System	21:15
10	Personalizing Care for LVAD Recipients	15:36
11	Heart Allocation by Continuous Distribution: Are We Nearly There Yet?	15:14
12	Cardiogenic Shock: Advanced Therapies – Panel Discussion	09:50
13	Heart Failure: Practical AI Tools for Clinical Decision-Making	40:18
14	Heart Failure: Which Patients Can Undergo CABG and Valve Surgery?	17:13
15	Cardiogenic Shock: From Guidelines to Bedside	15:45
16	Temporary MCS Devices: Right Device, Right Patient, Right Time	17:05
17	HFpEF and Obesity: Tirzepatide Findings From the SUMMIT Trial and Substudies	14:54
18	HFpEF: Clinical Insights From FINEARTS-HF, RE-DEFINE-HF, and Substudies	12:32
19	Neuregulin and Other Regenerative Pathways in HFrEF	15:29
20	Heart Failure: Top Five Practice-Changing Clinical Trials – Panel Discussion	21:08
21	Heart Failure and CKM: Advancing Equitable Care	21:55
22	HF Population Health: From Individual Care to Care Networks	19:12
23	Reframing HF: Treating and Preventing the Syndrome, Its Causes, and Comorbid Conditions	31:39
24	Heart Failure Care at Scale: Population Health Strategies – Panel Discussion	11:48
25	The Role of Digitalis in HFrEF Therapeutics	16:03
26	Vericiguat for HFrEF: Results From the VICTOR Trial	10:54
27	HFrEF in the Device Era	15:39
28	AI in HF: From Risk Prediction to Workflow Integration	19:48
29	Gene Therapy for Cardiomyopathies: Why, Who, and How	15:13
30	Implications of a CD36 Genetic Variant as a Cause of Cardiomyopathy	16:17
31	Metabolic Health as a Therapeutic Target for HFrEF	18:02
32	HF: Expert Q&A on AI, Emerging Therapies, and Future Directions	18:34
33	Ambulatory PA Monitoring: Who, When, How?	14:34
34	When GDMT Isn’t Enough: Recognizing Advanced HFrEF	17:32
35	Heart Failure and Metabolic Disease: Expert Q&A	17:03
36	CKM (Cardio-Kidney-Metabolic) Care Models: Practical Implementation	18:34
37	HFpEF: Integrating Diet and Exercise Into Treatment	19:07
38	Cardiac Sarcoidosis Across the EF Spectrum	17:31
39	Cardio-Oncology in the Advanced HF Clinic	16:15
40	Structural Heart Disease: Which Patients with AS and HFrEF Benefit Most from TAVR?	16:36
41	Atrial Fibrillation in Heart Failure: Advances in Catheter Ablation and Arrhythmia Management	16:57